A-B-C分类揭示阿替利珠单抗/贝伐珠单抗治疗肝细胞癌的结局轨迹
这项国际多中心研究纳入1399例不可切除肝细胞癌患者,采用数据驱动的机器学习方法识别出三个亚组(A、B、C),各组在组织学、肝功能失代偿、进展模式及生存轨迹上存在显著差异,A组预后最佳,C组最差。
要点
- A-B-C分类基于基线临床、生物学和肿瘤特征,可区分不同预后轨迹。
- A组(47.5%)总生存期未达到中位,显著长于B组(18.2个月)和C组(14.1个月)。
- C组肿瘤分化差、巨梁状 Massive 亚型更多,无进展生存期最短(中位6.10个月)。
核心结论
- A-B-C分类可识别不可切除肝细胞癌患者在组织学、肝功能失代偿、进展模式和预后轨迹上的不同亚组。
研究设计与样本
- 国际多中心研究,纳入12个中心接受一线阿替利珠单抗/贝伐珠单抗治疗的不可切除肝细胞癌患者1399例(85%男性,75%肝硬化,39%门静脉侵犯,35%转移),分为推导队列(n=958)和验证队列(n=409)。
主要发现
- 识别出3个亚组:A组(47.5%)年龄较大、BMI较高、肝功能保留、多个小肿瘤;B组(11%)VP1/VP2门静脉侵犯、HBV感染率较高、代谢综合征较低;C组(41.2%)中度肝功能障碍、甲胎蛋白升高、VP3/VP4门静脉侵犯或高肿瘤负荷。
- C组肿瘤分化差(P=.02)和巨梁状 Massive 亚型更多(P=.02)。
- A组总生存期(中位未达到)长于B组(18.2个月)和C组(14.1个月),P<.0001;A组进展率25.1%低于B组34.3%和C组41.2%,P<.0001;A组无进展生存期中位10.93个月长于B组7.73个月和C组6.10个月,P<.0001。
- 各亚组与巴塞罗那临床肝癌分期、早期肝功能失代偿发生及进展模式相关(P<.001)。
临床怎么用
- A-B-C分类可用于不可切除肝细胞癌患者的预后分层,辅助临床试验设计和患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non a priori, data-driven machine learning approach to uncover subgroups with distinct profiles across a range of clinical and tumor-related endpoints. METHODS: This international study across 12 centers included patients with unresectable HCC receiving first-line atezolizumab/bevacizumab. Baseline clinical, biological, and tumor characteristics were collected. Clusters were correlated with clinical and tumor-related outcomes, including RECIST 1.1 response, histology, hepatic decompensation, patterns of progression, overall survival (OS) and progression-free survival (PFS). RESULTS: Among 1399 patients (85% male; 75% cirrhotic; 39% with portal vein invasion [PVI]; 35% with metastasis), divided into derivation (n = 958) and validation (n = 409) cohorts, we identified 3 subgroups: Cluster A (47.5% patients): older age, higher body mass index (BMI), preserved liver function, multiple small tumors; Cluster B (11%): VP1/VP2 PVI, higher hepatitis B virus (HBV), and lower metabolic syndrome; Cluster C (41.2%): moderate liver dysfunction, elevated alpha-fetoprotein, and either VP3/VP4 PVI or high tumor burden. Cluster C had poor tumor differentiation (P = .02) and more macrotrabecular massive subtype (P = .02). Cluster A had longer OS (median not reached) vs Clusters B (18.2 months) and C (14.1 months; P < .0001), lower progression rates (25.1% vs 34.3% and 41.2%; P < .0001), and longer PFS (median 10.93 vs 7.73 and 6.10 months; P < .0001). Clusters correlated with prognosis across Barcelona Clinic Liver Cancer stages, occurrence of early hepatic decompensation and patterns of progression (P < .001). CONCLUSIONS: The Atezolizumab-Bevacizumab-Cluster (A-B-C) classification for unresectable HCC identified subgroups with histology, hepatic decompensation, and patterns of progression, and prognostic trajectories, informing hypothesis generation for trial design and patient selection.
引用
- Campani C, Galvanin C, Shim JH, et al. The "A-B-C" Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab. Clin Gastroenterol Hepatol. 2025. PMID: 41308896. doi:10.1016/j.cgh.2025.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。